Abstract: The present disclosure pertains to a GUCY2C-binding polypeptide and uses thereof and, specifically, to a GUCY2C-binding polypeptide, a fusion protein including same, a chimeric antigen receptor, an immune cell expressing the chimeric antigen receptor, and a use thereof for treatment and/or diagnosis of cancer.
| # | Name | Date |
|---|---|---|
| 1 | 202317066717-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [05-10-2023(online)].pdf | 2023-10-05 |
| 2 | 202317066717-STATEMENT OF UNDERTAKING (FORM 3) [05-10-2023(online)].pdf | 2023-10-05 |
| 3 | 202317066717-Sequence Listing in txt [05-10-2023(online)].txt | 2023-10-05 |
| 4 | 202317066717-Sequence Listing in PDF [05-10-2023(online)].pdf | 2023-10-05 |
| 5 | 202317066717-REQUEST FOR EXAMINATION (FORM-18) [05-10-2023(online)].pdf | 2023-10-05 |
| 6 | 202317066717-PROOF OF RIGHT [05-10-2023(online)].pdf | 2023-10-05 |
| 7 | 202317066717-PRIORITY DOCUMENTS [05-10-2023(online)].pdf | 2023-10-05 |
| 8 | 202317066717-POWER OF AUTHORITY [05-10-2023(online)].pdf | 2023-10-05 |
| 9 | 202317066717-FORM 18 [05-10-2023(online)].pdf | 2023-10-05 |
| 10 | 202317066717-FORM 1 [05-10-2023(online)].pdf | 2023-10-05 |
| 11 | 202317066717-DRAWINGS [05-10-2023(online)].pdf | 2023-10-05 |
| 12 | 202317066717-DECLARATION OF INVENTORSHIP (FORM 5) [05-10-2023(online)].pdf | 2023-10-05 |
| 13 | 202317066717-COMPLETE SPECIFICATION [05-10-2023(online)].pdf | 2023-10-05 |
| 14 | 202317066717-FORM 3 [27-03-2024(online)].pdf | 2024-03-27 |